

# Yeon Hee Park

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9171569/publications.pdf>

Version: 2024-02-01

191  
papers

9,329  
citations

101543

36  
h-index

48315

88  
g-index

196  
all docs

196  
docs citations

196  
times ranked

10036  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab for Early Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 810-821.	27.0	1,542
2	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 610-621.	27.0	1,143
3	Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 387, 9-20.	27.0	854
4	Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. <i>Nature Communications</i> , 2017, 8, 15081.	12.8	743
5	Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 1143-1154.	27.0	474
6	Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 556-567.	27.0	444
7	Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. <i>Lancet Oncology</i> , The, 2020, 21, 1155-1164.	10.7	274
8	Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1269-1282.	10.7	207
9	Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. <i>Lancet Oncology</i> , The, 2021, 22, 489-498.	10.7	157
10	Prevalence and detection of low-allele-fraction variants in clinical cancer samples. <i>Nature Communications</i> , 2017, 8, 1377.	12.8	137
11	Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. <i>Nature Communications</i> , 2018, 9, 1725.	12.8	122
12	A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 255-266.	2.5	96
13	A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. <i>British Journal of Cancer</i> , 2019, 120, 475-480.	6.4	92
14	Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. <i>Nature Communications</i> , 2020, 11, 6175.	12.8	92
15	Insights Into Breast Cancer in the East vs the West. <i>JAMA Oncology</i> , 2019, 5, 1489.	7.1	90
16	Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1750-1759.	10.7	86
17	Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy: KCSG-BR07-02. <i>Journal of Clinical Oncology</i> , 2013, 31, 1732-1739.	1.6	78
18	Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 809-817.	2.5	76

#	ARTICLE	IF	CITATIONS
19	Prognostic impact of FOXP3 expression in triple-negative breast cancer. <i>Acta Oncologica</i> , 2013, 52, 73-81.	1.8	72
20	A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (<math>\leq 1\text{cm}</math>) invasive breast cancer: who might be possible candidates for adjuvant treatment?. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 653-661.	2.5	65
21	Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer. <i>Oncotarget</i> , 2015, 6, 43731-43742.	1.8	63
22	Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173.. <i>Journal of Clinical Oncology</i> , 2017, 35, 556-556.	1.6	60
23	HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis. <i>BMC Medicine</i> , 2022, 20, 105.	5.5	60
24	Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer. <i>Cancer Research and Treatment</i> , 2016, 48, 1338-1350.	3.0	56
25	Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance. <i>Cancer Research and Treatment</i> , 2019, 51, 737-747.	3.0	53
26	Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2 <sup>-</sup> ) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1006-1006.	1.6	52
27	Gene Expression Profiling of Breast Cancer Brain Metastasis. <i>Scientific Reports</i> , 2016, 6, 28623.	3.3	51
28	AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1007-1007.	1.6	51
29	BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)â€”Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).. <i>Journal of Clinical Oncology</i> , 2021, 39, 1023-1023.	1.6	49
30	Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer. <i>Oncology</i> , 2018, 7, e1466768.	4.6	48
31	Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway. <i>Biochemical and Biophysical Research Communications</i> , 2013, 439, 275-279.	2.1	47
32	A phase II trial of the panâ€”HER inhibitor poziotinib, in patients with HER2â€”positive metastatic breast cancer who had received at least two prior HER2â€”directed regimens: results of the NOV120101â€”203 trial. <i>International Journal of Cancer</i> , 2018, 143, 3240-3247.	5.1	46
33	Ets-1 upregulates HER2-induced MMP-1 expression in breast cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2008, 377, 389-394.	2.1	45
34	The relationship between nuclear factor (NF)-â€”B family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment. <i>Scientific Reports</i> , 2016, 6, 31804.	3.3	44
35	Immune gene expression profiling reveals heterogeneity in luminal breast tumors. <i>Breast Cancer Research</i> , 2019, 21, 147.	5.0	43
36	Role of adjuvant chemotherapy in malignant mucosal melanoma of the head and neck. <i>Oral Oncology</i> , 2010, 46, 607-611.	1.5	41

#	ARTICLE	IF	CITATIONS
37	Intratumor heterogeneity inferred from targeted deep sequencing as a prognostic indicator. <i>Scientific Reports</i> , 2019, 9, 4542.	3.3	40
38	Prognostic value of ERBB4 expression in patients with triple negative breast cancer. <i>BMC Cancer</i> , 2016, 16, 138.	2.6	39
39	Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.. <i>Journal of Clinical Oncology</i> , 2022, 40, 503-503.	1.6	38
40	Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer. <i>Oncotarget</i> , 2015, 6, 32027-32038.	1.8	36
41	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2020, 31, 451-469.	1.2	34
42	Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01). <i>Cancer Research and Treatment</i> , 2019, 51, 43-52.	3.0	34
43	Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 475-489.	2.5	33
44	The impact of race and ethnicity in breast cancer—disparities and implications for precision oncology. <i>BMC Medicine</i> , 2022, 20, 72.	5.5	33
45	Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy. <i>European Journal of Cancer</i> , 2014, 50, 698-705.	2.8	32
46	Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 526-526.	1.6	32
47	Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 507-516.	2.3	31
48	The nuclear factor-kappa B pathway and response to treatment in breast cancer. <i>Pharmacogenomics</i> , 2017, 18, 1697-1709.	1.3	31
49	Treating HR+/HER2~ breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 549-559.	2.5	29
50	Interaction between <i>BCL2</i> and <i>Interleukin-10</i> Gene Polymorphisms Alter Outcomes of Diffuse Large B-Cell Lymphoma following Rituximab Plus CHOP Chemotherapy. <i>Clinical Cancer Research</i> , 2009, 15, 2107-2115.	7.0	28
51	Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC). <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 753-761.	2.3	27
52	Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 737-745.	2.5	27
53	Genetic and Clinical Characteristics of Phyllodes Tumors of the Breast. <i>Translational Oncology</i> , 2018, 11, 18-23.	3.7	26
54	A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-positive solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1039-1039.	1.6	26

#	ARTICLE	IF	CITATIONS
55	Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency. <i>Scientific Reports</i> , 2016, 6, 33035.	3.3	24
56	Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment. <i>Clinical Breast Cancer</i> , 2018, 18, e1141-e1147.	2.4	24
57	Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study. <i>BMC Cancer</i> , 2015, 15, 693.	2.6	23
58	Prevalence and clinical outcomes of young breast cancer (YBC) patients according to intrinsic breast cancer subtypes: Single institutional experience in Korea. <i>Breast</i> , 2015, 24, 213-217.	2.2	23
59	Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. <i>European Journal of Cancer</i> , 2017, 86, 385-393.	2.8	23
60	Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1. <i>Journal of Clinical Oncology</i> , 2021, 39, 2005-2015.	1.6	23
61	Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes. <i>Oncotarget</i> , 2017, 8, 27997-28007.	1.8	23
62	Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period. <i>Journal of Pathology and Translational Medicine</i> , 2017, 51, 69-78.	1.1	21
63	A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 408-417.	7.0	21
64	Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response. <i>Oncotarget</i> , 2017, 8, 47400-47411.	1.8	21
65	The Value of Ki67 in Very Young Women with Hormone Receptor-Positive Breast Cancer: Retrospective Analysis of 9,321 Korean Women. <i>Annals of Surgical Oncology</i> , 2015, 22, 3481-3488.	1.5	20
66	Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. <i>Scientific Reports</i> , 2020, 10, 8753.	3.3	20
67	Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2- eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study. <i>Journal of Clinical Oncology</i> , 2022, 40, 589-589.	1.6	20
68	Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast. <i>Journal of Pathology and Translational Medicine</i> , 2020, 54, 95-102.	1.1	19
69	Clinical implication of Time To Brain Metastasis (TTBM) according to breast cancer subtypes. <i>SpringerPlus</i> , 2013, 2, 136.	1.2	18
70	Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 325-334.	2.5	18
71	Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data. <i>Cancer Research and Treatment</i> , 2019, 51, 727-736.	3.0	18
72	Trastuzumab deruxtecan for HER2+ advanced breast cancer. <i>Future Oncology</i> , 2022, 18, 7-19.	2.4	18

#	ARTICLE	IF	CITATIONS
73	Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA3-LBA3.	1.6	18
74	Prognostic Significance of a Complete Response on Breast MRI in Patients Who Received Neoadjuvant Chemotherapy According to the Molecular Subtype. <i>Korean Journal of Radiology</i> , 2015, 16, 986.	3.4	17
75	A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery. <i>International Journal of Cancer</i> , 2015, 136, 1976-1984.	5.1	17
76	Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02). <i>Breast Cancer Research and Treatment</i> , 2015, 152, 77-85.	2.5	17
77	Survival outcomes of breast cancer patients with brain metastases: A multicenter retrospective study in Korea (KROG 16-12). <i>Breast</i> , 2020, 49, 41-47.	2.2	16
78	The incidence and clinical features of PEGylated filgrastim-induced acute aortitis in patients with breast cancer. <i>Scientific Reports</i> , 2020, 10, 18647.	3.3	16
79	Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 385-395.	2.5	15
80	Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer. <i>JAMA Oncology</i> , 2022, 8, 1271.	7.1	15
81	PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis. <i>Journal of Breast Cancer</i> , 2018, 21, 382.	1.9	14
82	Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients. <i>International Journal of Cancer</i> , 2019, 145, 1669-1678.	5.1	14
83	Primary Peritoneal High-grade Serous Carcinoma Misinterpreted as Metastatic Breast Carcinoma: A Rare Encounter in Peritoneal Fluid Cytology. <i>Anticancer Research</i> , 2020, 40, 2933-2939.	1.1	14
84	Deep Learning-Based Prediction Model for Breast Cancer Recurrence Using Adjuvant Breast Cancer Cohort in Tertiary Cancer Center Registry. <i>Frontiers in Oncology</i> , 2021, 11, 596364.	2.8	14
85	A randomized phase II study of palbociclib plus exemestane with GNRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer (KCSG-BR 15-10). <i>TJ EQq1 1 0.784314 rgB14/Overl</i>		
86	Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy. <i>Oncotarget</i> , 2017, 8, 86423-86434.	1.8	14
87	Spontaneous regression in advanced squamous cell lung carcinoma. <i>Journal of Thoracic Disease</i> , 2016, 8, E235-E239.	1.4	13
88	Clinical features and prognosis of breast cancer with gastric metastasis. <i>Oncology Letters</i> , 2019, 17, 1833-1841.	1.8	13
89	Clinical Features and Outcomes of Invasive Breast Cancer: Age-Specific Analysis of a Modern Hospital-Based Registry. <i>Journal of Global Oncology</i> , 2019, 5, 1-9.	0.5	13
90	The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans. <i>Hereditary Cancer in Clinical Practice</i> , 2019, 17, 1.	1.5	13

#	ARTICLE	IF	CITATIONS
91	Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. <i>Breast</i> , 2022, 62, 52-60.	2.2	13
92	Clinical outcomes according to molecular subtypes in stage II-III breast cancer patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 329-336.	1.1	12
93	Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis. <i>Journal of Clinical Oncology</i> , 2020, 38, 1036-1036.	1.6	12
94	Lymph Node Ratio as a Risk Factor for Locoregional Recurrence in Breast Cancer Patients with 10 or More Axillary Nodes. <i>Journal of Breast Cancer</i> , 2016, 19, 169.	1.9	11
95	Fluorine-18 fluorodeoxyglucose positron emission tomography imaging of T-lymphoblastic lymphoma patients. <i>Oncology Letters</i> , 2016, 12, 1620-1622.	1.8	11
96	Elevated Level of Nerve Growth Factor (NGF) in Serum-Derived Exosomes Predicts Poor Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. <i>Cancers</i> , 2021, 13, 5260.	3.7	11
97	Characterization of Durable Responder for Capecitabine Monotherapy in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, e287-e292.	2.4	10
98	Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea. <i>Cancer Research and Treatment</i> , 2016, 48, 1382-1388.	3.0	10
99	A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 617-625.	2.5	10
100	Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study). <i>European Journal of Cancer</i> , 2018, 103, 127-136.	2.8	10
101	Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 649-656.	2.5	10
102	Breast Cancer Epidemiology of the Working-Age Female Population Reveals Significant Implications for the South Korean Economy. <i>Journal of Breast Cancer</i> , 2018, 21, 91.	1.9	10
103	Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 747-757.	2.5	10
104	Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 653-663.	2.5	10
105	Clinical Outcomes and Prognostic Factors of Pathologic N3 Breast Cancer Treated With Modern Standard Treatments. <i>Clinical Breast Cancer</i> , 2015, 15, 512-518.	2.4	9
106	Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2-positive metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16). <i>British Journal of Cancer</i> , 2019, 121, 985-990.	6.4	9
107	Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase II Trial (KCSG-BR 15-10). <i>Cancers</i> , 2020, 12, 3265.	3.7	9
108	A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPtello290). <i>Journal of Clinical Oncology</i> , 2020, 38, TPS1109-TPS1109.	1.6	9

#	ARTICLE	IF	CITATIONS
109	Abstract OT2-11-05: SERENA-6: A Phase III study to assess the efficacy and safety of AZD9833 (camizestrant) compared with aromatase inhibitors when given in combination with palbociclib or abemaciclib in patients with HR+/HER2- metastatic breast cancer with detectable $\text{ESR1}$ who have not experienced disease progression on first-line therapy. <i>Cancer Research</i> , 2022, 82, OT2-11-05-OT2-11-05.	0.9	9
110	Which Patients with Left Breast Cancer Should be Candidates for Heart-Sparing Radiotherapy?. <i>Journal of Breast Cancer</i> , 2018, 21, 206.	1.9	8
111	Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea. <i>BMC Cancer</i> , 2019, 19, 84.	2.6	8
112	Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 1315-1325.	3.4	8
113	Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience. <i>Cancer Research and Treatment</i> , 2022, , .	3.0	8
114	Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay. <i>Oncotarget</i> , 2015, 6, 24499-24510.	1.8	7
115	Body Mass Index with Tumor 18F-FDG Uptake Improves Risk Stratification in Patients with Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0165814.	2.5	7
116	Isolated pachymeningeal metastasis from breast cancer: Clinical features and prognostic factors. <i>Breast</i> , 2017, 35, 109-114.	2.2	7
117	Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity. , 2020, 8, e001199.		7
118	Prospective longitudinal multi-omics study of palbociclib resistance in hormone receptor+/HER2-metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1013-1013.	1.6	7
119	An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer. <i>Targeted Oncology</i> , 2021, 16, 701-741.	3.6	7
120	A phase II, randomized, open-label 3-arm clinical trial of fulvestrant (F) plus goserelin (G) versus anastrozole (A) plus goserelin (G) versus goserelin (G) alone for hormone receptor (HR) positive, tamoxifen (T) pretreated premenopausal women with recurrent or metastatic breast cancer (MBC) (KCSG BR10-04).. <i>Journal of Clinical Oncology</i> , 2017, 35, 1041-1041.	1.6	7
121	The effect of androgen receptor expression on clinical characterization of metastatic breast cancer. <i>Oncotarget</i> , 2017, 8, 8693-8706.	1.8	7
122	Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results. <i>Cancer Research and Treatment</i> , 2017, 49, 423-429.	3.0	7
123	Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer?. <i>Frontiers in Oncology</i> , 2021, 11, 759150.	2.8	7
124	Validation and Comparison of CS-IHC4 Scores with a Nomogram to Predict Recurrence in Hormone Receptor-Positive Breast Cancers. <i>Oncology</i> , 2014, 86, 279-288.	1.9	6
125	Prognostic Modeling in Pathologic N1 Breast Cancer Without Elective Nodal Irradiation After Current Standard Systemic Management. <i>Clinical Breast Cancer</i> , 2015, 15, e197-e204.	2.4	6
126	Clinicopathological Features and Prognostic Factors Affecting Survival Outcomes in Isolated Locoregional Recurrence of Breast Cancer: Single-Institutional Series. <i>PLoS ONE</i> , 2016, 11, e0163254.	2.5	6



#	ARTICLE	IF	CITATIONS
127	Genomic characteristics of breast cancer to predict response of neoadjuvant chemotherapy and long-term prognosis.. Journal of Clinical Oncology, 2021, 39, 557-557.	1.6	6
128	Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13). Cytokine, 2021, 142, 155487.	3.2	6
129	Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer (TNBC) with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21).. Journal of Clinical Oncology, 2020, 38, TPS597-TPS597.	1.6	6
130	Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach. Cancers, 2021, 13, 5835.	3.7	6
131	Abstract PD13-06: Neoadjuvant giredestrant (GDC-9545) + palbociclib versus anastrozole + palbociclib in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer: Primary analysis of the randomized, open-label, phase II coopERA breast cancer study. Cancer Research, 2022, 82, PD13-06-PD13-06.	0.9	6
132	Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study. Blood Cancer Journal, 2021, 11, 200.	6.2	6
133	Dermatomyositis and Paclitaxel-Induced Cutaneous Drug Eruption Associated with Metastatic Breast Cancer. Journal of Breast Cancer, 2015, 18, 195.	1.9	5
134	Proportion and Clinical Outcomes of Postoperative Radiotherapy Omission after Breast-Conserving Surgery in Women with Breast Cancer. Journal of Breast Cancer, 2015, 18, 50.	1.9	5
135	Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG) Tj ETQq1 1 0.784314 5gBT /Ove	0.9	5
136	New brain metastases after whole-brain radiotherapy of initial brain metastases in breast cancer patients: the significance of molecular subtypes (KROG 16-12). Breast Cancer Research and Treatment, 2021, 186, 453-462.	2.5	5
137	Ki-67 level in hormone receptor positive breast cancer patients: A retrospective review of 9,061 Korean women.. Journal of Clinical Oncology, 2013, 31, 551-551.	1.6	5
138	Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses. Cancer Research, 2022, 82, GS1-01-GS1-01.	0.9	5
139	Clinical presentation of carcinoma of unknown primary: 14 years of experience. Tumor Biology, 2011, 32, 45-51.	1.8	4
140	Small node-negative (T1b-cN0) invasive hormone receptor-positive breast cancers: Is there a subpopulation that might have benefit from adjuvant chemotherapy?. Breast Cancer Research and Treatment, 2012, 133, 247-255.	2.5	4
141	Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib. Breast Cancer Research and Treatment, 2020, 184, 743-753.	2.5	4
142	Impact on Survival of Regular Postoperative Surveillance for Patients with Early Breast Cancer. Cancer Research and Treatment, 2015, 47, 765-773.	3.0	4
143	Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer. Cancer Research and Treatment, 2022, 54, 1130-1137.	3.0	4
144	Meeting Highlights: The First Korean Breast Cancer Treatment Consensus Conference. Journal of Breast Cancer, 2014, 17, 308.	1.9	3

#	ARTICLE	IF	CITATIONS
145	The Impacts of Inclusion in Clinical Trials on Outcomes among Patients with Metastatic Breast Cancer (MBC). <i>PLoS ONE</i> , 2016, 11, e0149432.	2.5	3
146	Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11). <i>Breast Cancer Research and Treatment</i> , 2019, 178, 367-377.	2.5	3
147	Impact of a topical lotion, CG428, on permanent chemotherapy-induced alopecia in breast cancer survivors: a pilot randomized double-blind controlled clinical trial (VOLUME RCT). <i>Supportive Care in Cancer</i> , 2020, 28, 1829-1837.	2.2	3
148	A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3113-3113.	1.6	3
149	Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 1100-1106.	1.7	3
150	Abstract P1-18-03: Alpelisib + fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), <i>PIK3CA</i> -mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + aromatase inhibitor (AI): 18-month follow-up of BYLieve Cohort A. <i>Cancer Research</i> , 2022, 82, P1-18-03-P1-18-03.	0.9	3
151	Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211065.	3.2	3
152	Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), <i>PIK3CA</i> -mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1018-1018.	1.6	3
153	What is the best treatment for primary breast lymphoma? Combined modality should be adapted according to the risk stratification. <i>Leukemia and Lymphoma</i> , 2006, 47, 2011-2012.	1.3	2
154	Local Laboratory Testing of Germline BRCA Mutations vs. Myriad: A Single-Institution Experience in Korea. <i>Diagnostics</i> , 2021, 11, 370.	2.6	2
155	Ventriculoperitoneal Shunt for CNS Metastasis in Breast Cancer: Clinical Outcomes Based on Intrinsic Subtype. <i>Clinical Breast Cancer</i> , 2021, 21, e402-e414.	2.4	2
156	A phase III, multicenter, randomized trial of maintenance versus observation after achieving clinical response in patients with metastatic breast cancer who received six cycles of gemcitabine plus paclitaxel as first-line chemotherapy (KCSG-BR 0702, NCT00561119).. <i>Journal of Clinical Oncology</i> , 2012, 30, 1003-1003.	1.6	2
157	Patient-reported outcomes (PROs) in patients (pts) with <i>PIK3CA</i> -mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) from SOLAR-1.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1039-1039.	1.6	2
158	Abstract PD10-03: BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC): Results from Arm 1 D + paclitaxel (P), Arm 2 D+P + capivasertib (C), and Arm 5 D+P + oleclumab (O). <i>Cancer Research</i> , 2022, 82, PD10-03-PD10-03.	0.9	2
159	Limited Supraclavicular Radiation Field in Breast Cancer With 10 Positive Axillary Lymph Nodes. <i>Clinical Breast Cancer</i> , 2016, 16, e15-e21.	2.4	1
160	The Role of Chemotherapy in Patients With HER2-Negative Isolated Locoregional Recurrence of Breast Cancer: A Multicenter Retrospective Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 653243.	2.8	1
161	Favorable prognostic factors of oligometastatic breast cancer: A subset analysis of OLIGO-BC1.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1026-1026.	1.6	1
162	Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL). <i>Cancer Research and Treatment</i> , 2021, 53, 695-702.	3.0	1

#	ARTICLE	IF	CITATIONS
163	Role of HER2 copy number amplification and PI3K pathway as a biomarker for patients with HER2+ MBC treating with Poziotinib, pan-HER TKI.. Journal of Clinical Oncology, 2018, 36, e13009-e13009.	1.6	1
164	Intestinal Marginal Zone B-Cell Lymphoma of MALT Type: Clinical Manifestation and Outcome of a Rare Disease.. Blood, 2006, 108, 4742-4742.	1.4	1
165	Intra-tumoral Metastatic Double Primary Carcinoma: Synchronous Metastatic Tumor in Lung from Breast and Thyroid Carcinoma. Cancer Research and Treatment, 2014, 46, 200-203.	3.0	1
166	A phase II, multicenter, randomized trial of eribulin plus gemcitabine (EG) vs. paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer (MBC) as first-line chemotherapy (KCSG BR13-11, NCT02263495).. Journal of Clinical Oncology, 2017, 35, 1082-1082.	1.6	1
167	International retrospective cohort study of locoregional and systemic therapy in oligometastatic breast cancer (OLIGO-BC1).. Journal of Clinical Oncology, 2020, 38, 1025-1025.	1.6	1
168	Efficacy of a tailored moisturizer for reducing chemotherapy-induced skin dryness in breast cancer patients: A randomized controlled clinical trial. Journal of the American Academy of Dermatology, 2022, 87, 858-860.	1.2	1
169	338â€¦Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study. , 2021, 9, A364-A364.		1
170	Novel prognostic classification predicts overall survival of patients receiving salvage whole-brain radiotherapy for recurrent brain metastasis from breast cancer: A recursive partitioning analysis (KROG 16-12). Breast, 2021, 60, 272-278.	2.2	1
171	Abstract OT1-14-02: Phase 3 study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09. Cancer Research, 2022, 82, OT1-14-02-OT1-14-02.	0.9	1
172	Abstract PD2-08: Serial genomic profiling reveals molecular mechanisms of breast cancer resistance to palbociclib. Cancer Research, 2022, 82, PD2-08-PD2-08.	0.9	1
173	The Pattern of Care for Brain Metastasis from Breast Cancer over the Past 10 Years in Korea: A Multicenter Retrospective Study (KROG 16-12). Cancer Research and Treatment, 2022, 54, 1121-1129.	3.0	1
174	Diversity, inclusion, and patient (pt)-centricity in the randomized, double-blind, phase III ASTEFANIA study of ado-trastuzumab emtansine (T-DM1) ± atezolizumab in pts with HER2-positive early breast cancer (EBC) with residual invasive disease after preoperative chemotherapy and anti-HER2 therapy.. Journal of Clinical Oncology, 2022, 40, e12504-e12504.	1.6	1
175	Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience. Cancers, 2020, 12, 1306.	3.7	0
176	Abstract P20: Continuity of oncology clinical trials during the Coronavirus Disease-2019 pandemic in Korea. , 2021, , .		0
177	Multicenter study for brain metastasis from breast cancer in Korea: The significance of molecular subtype (Korean Radiation Oncology Group 1612).. Journal of Clinical Oncology, 2021, 39, e14008-e14008.	1.6	0
178	A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors. Investigational New Drugs, 2021, 39, 1624-1632.	2.6	0
179	Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11). ESMO Open, 2021, 6, 100236.	4.5	0
180	Nongastric Marginal Zone B-Cell Lymphoma: A Prognostic Model from a Retrospective Multicenter Study.. Blood, 2007, 110, 1361-1361.	1.4	0

#	ARTICLE	IF	CITATIONS
181	Contribution of clinical trials to improved clinical outcomes for patients with metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2015, 33, e12596-e12596.	1.6	0
182	A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy.. Journal of Clinical Oncology, 2017, 35, 10108-10108.	1.6	0
183	Quality of life(QoL) outcomes including neuropathy associated scale (FACT-F) from a phase II, multicenter, randomized trial of eribulin plus gemcitabine(EG) versus paclitaxel plus gemcitabine(PG) as first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)- negative metastatic breast cancer(MBC): Korean Cancer Study Group trial (KCSG BR13-11).. Journal of Clinical Oncology, 2018, 36, 10117-10117.	1.6	0
184	Use of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with cytology proven axillary node-positive breast cancer at diagnosis.. Journal of Clinical Oncology, 2018, 36, e12640-e12640.	1.6	0
185	288â€¦A phase 1 study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors. , 2020, , .		0
186	Abstract P1-08-07: Prediction model of the response of neoadjuvant chemotherapy and long term survival according to multi-omic profiling in cooperation with clinicopathologic features in patients with breast cancer. Cancer Research, 2022, 82, P1-08-07-P1-08-07.	0.9	0
187	Abstract P1-16-01: Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer: A randomized, open-label, multicenter, phase II trial (KCSG-BR15-17). Cancer Research, 2022, 82, P1-16-01-P1-16-01.	0.9	0
188	Abstract P1-19-03: Phase II trial of durvalumab and tremelimumab in the hormone receptor-positive metastatic breast cancer with high tumor mutational burden selected by whole exome sequencing: Korean cancer study group trial (KCSG BR17-04). Cancer Research, 2022, 82, P1-19-03-P1-19-03.	0.9	0
189	Abstract P3-13-08: Fusion analysis including NTRK fusion in breast cancers (BC): From RNASeq data analysis from 629 BC tissue samples. Cancer Research, 2022, 82, P3-13-08-P3-13-08.	0.9	0
190	Abstract P5-16-03: Phase II study of trastuzumab biosimilar (HerzumaÂ®) plus gedatolisib in patients with HER-2 positive metastatic breast cancer who progressed after 2 or more HER-2 directed chemotherapy (BR 18-13, KM-10A): Interim analysis. Cancer Research, 2022, 82, P5-16-03-P5-16-03.	0.9	0
191	Abstract P1-21-01: Multicenter study for brain metastasis from breast cancer in Korea: The significance of molecular subtype (KROG 1612). Cancer Research, 2022, 82, P1-21-01-P1-21-01.	0.9	0